IRWD Ironwood Pharmaceuticals, Inc.
Healthcare$3.92+1.82%ClosedMarket Cap: $645.3M
As of 2026-05-25
Valuation
P/E (TTM)
24.65
PEG
0.01
P/B
-2.95
P/S
1.78
EV/EBITDA
4.97
DCF Value
$6.11
FCF Yield
17.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.6%
Operating Margin
55.8%
Net Margin
28.3%
ROE
-38.9%
ROA
23.5%
ROIC
30.0%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $106.5M | 99.6% | $72.5M | $40.8M | $— | — |
| Q4 null | $47.7M | 100.0% | $6.6M | $-2.3M | $— | — |
| FY null | $296.2M | 100.0% | $118.8M | $24.0M | $— | — |
| Q3 null | $122.1M | 99.6% | $77.7M | $40.1M | $— | — |
| Q2 null | $85.2M | 99.5% | $45.1M | $23.6M | $— | — |
| Q1 null | $41.1M | 33.3% | $-29.1M | $-37.4M | $— | — |
| Q4 null | $90.5M | 100.0% | $31.5M | $2.3M | $— | — |
| FY null | $351.4M | 97.9% | $93.1M | $880.0K | $— | — |
| Q3 null | $91.6M | 67.4% | $25.6M | $3.6M | $— | — |
| Q2 null | $94.4M | 100.0% | $25.0M | $-860.0K | $— | — |
| Q1 null | $74.9M | 65.5% | $11.0M | $-4.2M | $— | — |
| Q4 2023 | $117.6M | 100.0% | $37.6M | $-1.1M | $-0.01 | — |